Fulcrum Therapeutics (FULC) Return on Capital Employed (2019 - 2026)
Fulcrum Therapeutics' (FULC) quarterly Return on Capital Employed came in at 24.97% in Q1 2026, down 1985.0% year-on-year from 1.32% in Q1 2025, and up 18.26% on a QoQ basis from 30.54% in Q4 2025.
Fulcrum Therapeutics (FULC) Return on Capital Employed (2019 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 8 years of Return on Capital Employed data on file, last reported at 24.97% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1985.0% year-over-year to 24.97% in Q1 2026; TTM through Mar 2026 was 24.97%, a 1985.0% decrease from a year earlier, with the FY2025 full-year figure at 28.21%, down 1939.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 24.97%, up from 30.54% in the prior quarter.
- Over the last five years, Return on Capital Employed for FULC reached as high as 5.12% in Q1 2025 and fell as low as 56.33% in Q2 2022.
- Historically, Return on Capital Employed has averaged 34.37% across 5 years, with a median of 38.77% in 2025.
- On a YoY basis, Return on Capital Employed climbed as much as 4289 bps in 2025 and fell as far as 2758 bps in 2025.
- Year by year, Return on Capital Employed stood at 51.04% in 2022, then increased by 15 bps to 43.46% in 2023, then jumped by 81 bps to 8.46% in 2024, then sank by 261 bps to 30.54% in 2025, then climbed by 18 bps to 24.97% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 24.97% in Q1 2026, 30.54% in Q4 2025, and 38.77% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Fulcrum Therapeutics | 285.43 Mn | 285.43 Mn | - | -24.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.97% |
| Dec 31, 2025 | -30.54% |
| Sep 30, 2025 | -38.77% |
| Jun 30, 2025 | -37.38% |
| Mar 31, 2025 | -5.12% |
| Dec 31, 2024 | -8.46% |
| Sep 30, 2024 | -11.19% |
| Jun 30, 2024 | -13.07% |
| Mar 31, 2024 | -48.01% |
| Dec 31, 2023 | -43.46% |
| Sep 30, 2023 | -40.16% |
| Jun 30, 2023 | -36.35% |
| Mar 31, 2023 | -44.13% |
| Dec 31, 2022 | -51.04% |
| Sep 30, 2022 | -52.29% |
| Jun 30, 2022 | -56.33% |
| Mar 31, 2022 | -43.00% |
| Dec 31, 2021 | -35.85% |
| Sep 30, 2021 | -42.75% |
| Jun 30, 2021 | -59.05% |